Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

$9M Investment in Blockchain-backed Healthcare Data Company, Rymedi


Rymedi, a blockchain-backed healthcare data transfer and workflow automation platform that is announcing they've secured an investment of $9M with Whitestar Capital, RW3 Ventures, and other angel investors. I thought you might be interested to know more about this. With patent-pending blockchain technology, Rymedi is quickly expanding to help shape the future of healthcare data infrastructures for better patient care on a global scale. The platform meets healthcare compliance standards worldwide, and its level of interoperability and ability to securely are unmatched. They are already serving over 1 million patients in over 1,200 locations across the US, Africa, and Australia and are rapidly increasing their reach with this investment.

GREENVILLE, S.C. , Oct. 26, 2023 /PRNewswire-PRWeb/ -- Rymedi, a healthcare data exchange platform with advanced blockchain security, has announced a Series A totaling $9 million with plans to expand the reach of their platform.

The round was co-led by RW3 Ventures and White Star Capital with participation from Blockchange Ventures, Avalanche's Blizzard Fund, and strategic angel investors from the healthcare industry. Rymedi, which serves over 1 million patients in over 1,200 locations across the US, Africa, and Australia, will use the financing to increase data security and healthcare record accessibility for patients while reducing data entry errors and costs for healthcare data infrastructures on a global scale.

"We are always searching for great teams that are using blockchain technology to solve real-world problems with the potential to address global markets," said Pete Najarian, Managing Partner of RW3 Ventures. "The Rymedi team and product suite fit that thesis perfectly, and we are delighted to be on this journey with them. While healthcare data management has remained inefficient and expensive, we believe Rymedi's blockchain-based solution is having a meaningful impact on cost, connectivity, security, and user experience."

The Rymedi platform, which currently supports Clemson University and many other large organizations throughout the world, removes the friction of a manual, paper filled operation to quickly connect with customers and patients and scale lab processes with higher testing throughput and lower total cost of ownership.

"Our decentralized data platform is diminishing roadblocks that healthcare systems have faced for far too long," said David Stefanich, CEO and Founder of Rymedi. "Data entry errors and healthcare compliance issues slow the development of life-saving research, patient care, and occupational health processes. We are improving the overall healthcare experience with this technology and are proud to make a larger global impact as we scale our services with this round of funding."

In the areas of occupational health, clinical trials, and laboratory information management systems, it automates data transfer with flexible interoperability, streamlines data entry with real-time results, and meets global regulatory compliance standards with unrivaled security. This is all made possible by Rymedi's innovative blockchain-based backend, which is uniquely suited to facilitate data access across multiple parties and platforms.

"The current infrastructure for healthcare data exists across multiple disparate systems like EHRs and LIMs and has resulted in massive and inefficient data silos. For healthcare companies, this portends both higher costs and lost revenue, and for consumers, a suboptimal care experience," said Sep Alavi, General Partner of White Star Capital. "Couple this with increasing demands from consumers for value-based care, and you can start to visualize the scale of the opportunity for disruption. Rymedi's innovative solution serves as the connectivity layer between all of these silos and is consistent with our thesis that the design space for programmable & decentralized blockchain backends is massive."

ABOUT RYMEDI

Founded in 2018, Rymedi is revolutionizing data transfer and security on a global scale. The Rymedi blockchain platform meets multijurisdictional compliance so that data is securely transferred while meeting healthcare compliance standards worldwide. With over 1 million lives on the platform in over 1,200 locations in the US, Africa, and Australia, it is utilized for occupational health, laboratories, diagnostic devices, and clinical trials. The ease and efficiency of this robust platform increases revenue and efficiency and reduces cost for various healthcare infrastructures while protecting vital healthcare information with unmatched security.

Media Contact
Kristina Loughrey, Rymedi, 1 8643605848, [email protected], www.rymedi.com

SOURCE Rymedi


These press releases may also interest you

at 02:10
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance...

8 mai 2024
Tri-Tech Forensics, Inc. (Tri-Tech), a leading provider of tactical emergency medical solutions and human identification kits, is pleased to announce the acquisition of SAM® Medical (SAM Medical), a globally renowned provider of innovative medical...

8 mai 2024
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The...

8 mai 2024
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...

8 mai 2024
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

8 mai 2024
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...



News published on and distributed by: